Loading
A phase 2 trial of Selinexor, Daratumumab, Lenalidomide in multiple myeloma, run by US Oncology Research, active and no longer recruiting.
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma is a phase 2 interventional study registered as NCT04782687 by US Oncology Research, with 73 participants enrolled, started 2021-09-10 and due to reach its primary completion in 2026-05-31. Interventions recorded: Selinexor, Dexamethasone Oral, Daratumumab, Lenalidomide. Conditions listed: Multiple Myeloma, Myeloma Multiple, Kahler Disease, Myeloma, Plasma Cell. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Selinexor, Daratumumab, Lenalidomide, Multiple myeloma.
Shares Daratumumab, Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Monoclonal antibodies.
Shares Daratumumab, Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Monoclonal antibodies.
Shares Daratumumab, Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Monoclonal antibodies.
Shares Daratumumab, Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Monoclonal antibodies.
Shares McKesson / The US Oncology Network, Monoclonal antibodies, Small-molecule kinase inhibitors.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Multiple myeloma.
Shares Daratumumab, Lenalidomide, Monoclonal antibodies, Multiple myeloma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/